| INTRODUCTION
Synovial sarcoma can occur in both the pediatric and adult age range, mostly at 15 to 40 years of age, and is the most common nonrhabdomyosarcomatous soft tissue sarcoma (STS) in childhood. [1] [2] [3] [4] [5] [6] Its hallmark is a specific t(X;18) (p11.2;q11.2) chromosomal translocation resulting in a SYT-SSX-fusion. [7] [8] [9] [10] Though the majority of tumors arise in extremities with preference of the lower limbs, limited data are available for primary synovial sarcoma of the foot. The literature mainly consists of case reports and only few, very small case series. [11] [12] [13] [14] [15] [16] [17] This gap is astonishing as synovial sarcoma is reported to be the most common soft tissue sarcoma of the foot. 18, 19 It is widely known that the indication of chemotherapy in synovial sarcoma is discussed controversially between different practices and academic sites. Especially in Europe different treatment strategies have been developed over the years for pediatric and adult oncology protocols. 20, 21 Furthermore, there is no final consensus on local therapies.
Especially in tumors arising in the foot or ankle mutilating surgery is often considered. Surgical margin is a factor commonly considered to influence prognosis; positive margins are related to poor survival. [22] [23] [24] However, for localized SS it was also shown that R1-resection with irradiation achieved the same local control rate as R0. 20 The objective of the current study was to evaluate the outcome of a series of 32 patients of tumors located in the foot or ankle treated in the prospective CWS trials.
| MATERIAL AND METHODS
Patients treated over the period of 1980 to 2013 in the consecutive trials CWS-81, 25 CWS-86, 26 CWS-91, 27 and CWS-96, 28 CWS-2002-P 29 or the registry CWS-SoTiSaR were eligible for this analysis if they fulfilled the following criteria: (i) SS diagnosis proven by central reference review (including molecular confirmation since 2000), (ii) no evidence of metastases, 30 (iii) disease located at the foot or ankle, and (iv) no previous treatment. All CWS trials were prospective and approved by the appropriate ethics committees. Written informed consent was obtained from patients, guardians/parents or both. Data collection was performed as previously described. 27, 31 Disease was staged according to the clinical tumor-node-metastases (TNM) classification 32 and the Intergroup Rhabdomyosarcoma Study (intergroup rhabdomyosarcoma study (IRS)) postsurgical grouping system. 33 According to the former, T1 are tumors confined to the organ or tissue of origin, while T2 lesions invade contiguous structures. Regional node involvement is indicated as N0 or N1, based on histological or clinical/radiological assessments. 32 The IRS system categorizes patients in four groups based on the amount and extent of residual tumor after initial surgery: group I includes completely excised tumors with negative microscopic margins, group II indicates grossly resected tumors with microscopic residual disease, group III patients have macroscopic residual disease after incomplete resection or biopsy, and group IV patients have metastases at onset. 33 
| Treatment
Treatment included surgery, chemotherapy, and local irradiation based on the ongoing protocols at the time of diagnosis. Primary excision was generally attempted if complete and nonmutilating resection was considered feasible (if not, a biopsy was taken and chemotherapy was given to shrink the tumor and make it more amenable to subsequent surgery). We defined as primary reexcision any resurgery performed up to 4 weeks after an initially biopsy or inadequate resection and before any other treatment.
After initial surgery, the consecutive CWS protocols recommended chemotherapy in all patients. The recommended chemotherapeutic regimens were vincristine, actinomycin D, cyclophosphamide, and adriamycin (VACA) in CWS-81, 25 and vincristine, actinomycin-D, ifosfamide, adriamycin (VAIA)-regimen, which incorporates ifosfamide instead of cyclophosphamide, in CWS-86, 26 and in all protocols including and following CWS-96. 28, 29 The CWS-91 trial investigated therapy intensification with etoposide (etoposide, vincristine, actinomycin-D, ifosfamide, adriamycin (EVAIA)). 27 Since the CWS-96 protocol, the VAIA-regimen was used. 28, 29 Radiotherapy was recommended for all patients except for primary IRS Group I patients, where it was only recommended in CWS-86 and CWS-91. According to the respective CWS-protocol radiotherapy at total doses of 32 to 54.4 Gy dependent on response to chemotherapy and resection status was to be administered in analogy to recommendations for patients with rhabdomyosarcoma-like tumors.
25-28,34
| Surgical remission
Best surgery was defined as the best surgical result at the end of treatment independent from the number of procedures; it was categorized as the presence of a macroscopic (R2), or microscopic (R1) residual tumor or as a resection with free margins (R0). A second analysis was conducted in which second look biopsy without evidence of viable tumor cells was also considered as (R0). Mutilation was defined as loss of parts of the foot or the whole foot.
| Statistical methods
Statistics were calculated using SPSS 24 (SPSS, Chicago, IL).
Comparison of distribution was performed with the χ² test. Eventfree survival (EFS) and overall survival (OS) were calculated using the Kaplan-Meier estimator. 35 For OS, the time from diagnosis to death or last follow-up was calculated, for EFS the time from diagnosis to first relapse/progression, death or last follow-up. Confidence intervals (CIs) for the Kaplan-Meier estimator were computed using Greenwoods Formula 36 and are stated at the 95% level. For comparison of EFS and OS levels the log-rank test was used.
3 | RESULTS
| Patient and tumor characteristics
Among 330 patients with primary localized SS, 32 had their tumor at the foot or ankle. They were registered into trials CWS-81 (n = 3), 
or CWS-SoTiSaR (n = 4) from Germany (n = 29), Switzerland (n = 1), or Poland (n = 2). The sex distribution was nearly equal with only a slight male preponderance (Table 1) . Median age at diagnosis was 13.9 years (range, 1.4-25.5).
Localization of the primary tumor was as follows: ankle, 11 (34%);
heel, 1 (3%); sole of the foot, 10 (31%); back of the foot, 4 (13%); and toe, 5 (16%). In the remaining the exact localization within the foot was not documented for three tumors.
Eleven of the thirty-two patients had tumors larger than 5 cm (< 3 cm, n = 9; 3-5 cm, n = 9; < 5 cm, not further specified, n = 1;
5-10 cm, n = 9; >10 cm, n = 2; tumor size not documented, n = 2). (Table 2) .
Surgery was considered mutilating in 14 of 32 (44%) patients.
There was no detailed documentation of the functional outcome.
| Outcome
Median overall survival for all 32 patients was 6.2 years (range, 1.1-31.1), median event-free survival was 5.8 years (range, 1.1-16.4).
5-year EFS and OS rates were 80% and 86%, respectively ( Figure 1 ).
Eight patients developed recurrences (four local, four metastatic).
Five of 32 patients died, all of disease, thereof all four of four patients with a first metastatic recurrence and one of four patients with a local relapse (who had later suffered several subsequent local and metastatic relapses). Lung metastases were the ultimate cause of death in all five deceased patients.
At last follow-up, 27 patients were alive (median follow-up from initial diagnosis 6.7 years [range, 1.1-16.6]), 24 of these in first and 3 in second complete remission.
| Prognostic factors
None of the evaluated factors correlated with overall or event-free survival probabilities (Table 1) . The individual patients' data are shown in Table 2 .
| Radiotherapy
In the series of eight IRS I patients, six did not receive radiotherapy.
One of those six without radiotherapy suffered local and one metastatic relapse, respectively. The other four live in continuous first remission with median follow-up of 7.4 years. The two IRS I-patients with irradiation both relapsed (one local relapse, one metastatic relapse) ( Table 2 ).
In the series of 12 IRS group II patients, only one did not receive radiotherapy. This patient is alive in continuous remission with a follow-up of 12 years. Within the group of 11 irradiated patients two suffered local relapses, one of these died.
In the series of 12 IRS III group patients, seven did and five did not receive radiotherapy. Four of those five without radiotherapy had a secondary resection with free margins. None of those four suffered a local recurrence whereas one had a metastatic relapse. In one, further information about second look surgery is missing. In the group of seven IRS III patients with irradiation, none suffered recurrence. All are alive in first remission.
| DISCUSSION
Synovial sarcoma has been explored in depth since the first article written by Haagensen and Stout. 37 Though it is reported to be the most frequent soft tissue sarcoma of the foot, 18 only case reports and only few, very small case series are available. [11] [12] [13] [14] [15] [16] [17] In our analysis we describe a cohort of 32 patients presenting with synovial sarcoma of the foot or ankle. We consider the presented information to add valuable information, as it may facilitate communication and discussion with patients in this clinical scenario. As mutilating surgery is often considered, our special focus was on local therapies.
This retrospective analysis of prospectively treated patients has its limitations. Though it is to the best of knowledge the largest series in literature, the sample size is still limited. Tumor grading was not evaluable as it was not available for many of the patients included during the long recruitment period. Grading is an essential prognostic factor for extremity soft tissue sarcoma. [38] [39] [40] [41] [42] In former times synovial sarcoma was generally considered as a high grade tumor. 3 Nowadays, tumor grade is considered to be a very important predictive factor especially in synovial sarcoma. 43, 44 Nevertheless, our group could not provide evidence for this. 10 
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The 32 patients had a median age of 13.9 years (range, 1.4-25.5) with 16% of patients <10 years. Merely five of the patients were of adult age.
Similar to previous reports, we observed the male:female ratio to be nearly equal with only a slight male preponderance. 3, 20, 45 All patients except for one achieved a first complete remission with surgery. The only patient with a R2-status as best surgical result had no evidence of vital tumor cells in a second look biopsy conducted after radiotherapy and did not have disease progression for more than 6 years. This may be considered a complete remission following radiotherapy.
We found a 5-year event-free survival rate of 80% and a 5-year overall survival rate of 86%. This survival rate compares favorably to published data of synovial sarcoma at all sites. 3, [22] [23] [24] [45] [46] [47] The fact that our series comprises mainly pediatric patients may contribute to the favorable outcome. Our patients had a local recurrence rate of 12.5% and a distant metastases rate of 12.5% at first relapse.
Interestingly, all of the patients who died from disease within 5 years were male. In fact only one female patient died of disease.
Male gender has been proven as independent adverse prognostic factor in synovial sarcoma 4,10 whereas in other series the effect is verifiable without statistical significance 3,5,6,44 or not evident. 22, 48 Reasons for these inconsistent findings remain to be elucidated.
In literature, size, surgical margin, grade, and stage of the tumor have all been found to correlate with survival. Tumor size is the most commonly discussed prognostic factor, and it is suggested that this is also related to other prognostic factors (eg, stage, grade, vascular invasion, and extremity location). 23 Although the exact dimensions reported in the literature vary, better survival is generally seen in patients with a tumor smaller than 5 cm. [22] [23] [24] 46, 47 In our series of tumors at the foot and ankle, 63% patients had a tumor <5 cm, which seems relatively high when compared to previous reports of synovial sarcoma at all sites. 22, 24 For localized SS, tumor diameters of <5 cm are described in about half of the cases regardless of tumor site. 3, 20 The unusual tumor location might lead to an earlier detection of F I G U R E 1 Event-free and overall survival probability of 32 patients with localized synovial sarcoma of the foot or ankle. CI, confidence interval; EFS, event-free survival; OS, overall survival tumor mass. The administered chemotherapy combinations were trial-dependent. In our small series it is not possible to draw a conclusion with regard to intensive chemotherapy or maintenance chemotherapy. All patients were treated with chemotherapy except for one IRS I group patient.
Though the benefit of chemotherapy in the EFS and OS of synovial sarcoma is debated between different practices and academic sites and in particularly between pediatric and medical oncologists in Europe, 20, 21 four of six IRS group patients with available response to chemotherapy showed a reduction of tumor volume. Hence, chemotherapy might improve resectability in some tumors.
Neither resection status of primary resection nor best surgical result at any time was predictive for survival. Nevertheless, all tumors except for one were grossly resected. In one single patient with initial R2-resection and subsequent irradiation no vital tumor cells could be found in second look sampling biopsy. Consequently, no resection was performed. He remained in complete remission with a follow-up of 6.1 years. The application of radiotherapy was not significantly correlated with improved survival in this report, but EFS and OS probability was increased by 30% with the use of radiotherapy, respectively. We hypothesize that the low number of patients may limit the informative value of our study. Interestingly, in the IRS I group of our series the proportion of disease recurrence is considerably higher than in the other groups ( Unfortunately, it is impossible to draw a reliable, final conclusion concerning radiotherapy in synovial sarcoma of the foot or ankle from our small series. We think that it should not be omitted in patients with positive resection margins.
In summary, in our series of 32 patients with synovial sarcoma of the foot or ankle, resection with positive margins in combination with radiotherapy provided sufficient local control rates. Aggressive surgery to achieve a R0 resection did not improve survival. The role of radiotherapy after a delayed R0 resection remains unclear.
Nevertheless, there was no detailed information available concerning the long-term functional outcome. It would be of utmost importance to consider the late effects not only of surgery but also of radiotherapy. It is widely known, that the application of radiotherapy in children causes growth problems, especially in cases where epiphyseal plates are radiated. In some circumstances, function SCHEER ET AL.
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outcome from below knee amputation with use of modern prosthetic might be superior to foot sparing surgery followed by radiation.
Moreover, patient-reported outcomes might provide additional insight into how patients perceive treatment effects and may be helpful in determining how therapeutic interventions impact many aspects of a patients' life.
Further studies in synovial sarcoma might not only focus on the controversially discussed necessity of chemotherapy in different age groups and tumor stages but also on the required aggressiveness of local therapies. Future treatment recommendations might vary between different tumor sites.
In conclusion, our study is the largest cohorts of patients with synovial sarcoma of the foot or ankle reported to date. Using the same treatment strategy as used in extremity synovial sarcoma in general, the survival rate compares favorably to published data.
Further studies are needed to set the limits of minimally required aggressiveness of local therapies.
